Mounjaro hair loss: what trials show

Yes, hair loss can occur during treatment with tirzepatide, the active ingredient in Mounjaro. The clearest trial numbers come from the US Zepbound label, which covers the same medicine when it is used for weight management. In two pooled weight reduction trials, hair loss was reported by 4% to 5% of participants receiving tirzepatide and 1% receiving placebo^[1]. That result establishes a real association. It does not show that tirzepatide directly damages hair follicles, and it does not predict what will happen to one person.

The trial numbers

The prescribing information pools two randomized studies of adults with obesity or overweight. Among 958 people assigned to placebo, 1% reported hair loss. The rates were 5% among 630 participants assigned to 5 mg tirzepatide, 4% among 948 assigned to 10 mg, and 5% among 941 assigned to 15 mg^[1]. Because the rates do not rise steadily with dose, this table does not show a simple dose response pattern.

The same label gives a sharper split by sex. Hair loss was reported by 7.1% of women receiving tirzepatide and 1.3% of women receiving placebo. For men, the figures were 0.5% and 0%. The label says these reactions were associated with weight reduction. No participant receiving tirzepatide stopped treatment because of hair loss, while one placebo participant did^[1]. These figures describe reports recorded during the trials. They do not tell us how much hair was shed, how long shedding lasted, or whether every report had the same cause.

The weight change in the main obesity program was large enough to matter when interpreting that signal. In SURMOUNT 1, 2,539 adults without diabetes were randomized to tirzepatide or placebo for 72 weeks. Mean weight change ranged from 15.0% to 20.9% with tirzepatide, compared with 3.1% with placebo^[5]. The paper identifies gastrointestinal events as the most common adverse events. The later Zepbound label supplies the hair loss breakdown that is not present in the PubMed abstract.

Why Mounjaro and Zepbound labels differ

Mounjaro and Zepbound contain the same active medicine, tirzepatide. Their US labels summarize different development programs and indications. Mounjaro is labeled for type 2 diabetes. Zepbound is labeled for chronic weight management and other approved uses. The current Mounjaro label does not list hair loss among the common adverse reactions from its diabetes trials^[4]. The Zepbound label does list it after trials in which weight reduction was a central outcome^[1].

That difference should not be read as proof that one brand causes shedding and the other does not. A brand name does not change the molecule. Trial populations, follow up, event collection, and the amount of weight lost can all affect what appears in an adverse reaction table. The useful question is whether hair loss occurred during tirzepatide treatment and how strong the evidence is for a causal explanation.

The 2026 BMJ evidence adds context

A 2026 BMJ study used electronic health records from adults with type 2 diabetes to emulate a target trial. This method attempts to make an observational comparison resemble a randomized trial, but treatment was not randomly assigned. The analysis included 12,004 people starting a GLP 1 receptor agonist in one comparison and 11,964 in another^[2]. It examined the drug class rather than tirzepatide alone.

Compared with people starting an SGLT 2 inhibitor, GLP 1 receptor agonist users had a 37% higher relative hazard of a new alopecia diagnosis. Compared with people starting a DPP 4 inhibitor, the relative hazard was 68% higher. The confidence intervals excluded no difference in both comparisons. Subtype analysis pointed to nonscarring alopecia, and the authors described the absolute risk as low^[2]. Relative hazard is not the same as the percentage of people who will experience an event. These results also cannot be transferred directly to Mounjaro because several medicines were grouped together.

One week after that study appeared, BMJ published a short article titled "Does Mounjaro cause hair loss?"^[3]. Its PubMed record contains the title, author, date, and DOI but no abstract. We therefore do not use it as support for a mechanism or a numerical risk estimate. The trial label and the companion BMJ research record provide the checkable evidence behind the answer here.

What the evidence cannot separate

The available evidence leaves two explanations entangled. Tirzepatide may have an effect related to the medicine itself, or shedding may follow the weight change, reduced intake, illness, stress, or another condition present during treatment. The Zepbound label links reported hair loss with weight reduction, but an association inside a trial is not a mechanism experiment. The BMJ health record study found a class level association, but residual differences between treatment groups can remain even after statistical adjustment.

The records also do not answer whether a specific case is temporary diffuse shedding, patterned thinning that was already developing, an autoimmune form of alopecia, or another scalp disorder. Those conditions can look similar to someone noticing extra hair in a brush, yet they do not have the same causes. A percentage from a trial cannot diagnose the pattern in front of an individual reader.

What to do if you notice shedding

Do not stop a prescribed medicine solely on the basis of this article. Contact the clinician who prescribed it and describe when the shedding began, how quickly weight changed, whether food intake changed, and whether the loss is diffuse or patchy. Bring a complete list of medicines and supplements. That gives the clinician a better basis for deciding whether the timing fits treatment, weight change, or another cause that needs assessment.

The tirzepatide overview covers the medicine and its regulatory status. Readers comparing this signal across the class can also use the semaglutide overview. The practical bottom line is narrow: hair loss was reported more often with tirzepatide than placebo in weight reduction trials, but the cause and course of an individual case still require clinical assessment.